Quick Answer
Silo Pharma, Inc. reported Stockholders Equity of $6.31 million for the year ending 2025.
- Silo Pharma, Inc. showed an increase of +25.3% in Stockholders Equity from 2024 to 2025.
- This data is from Silo Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2010 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $1.20 million | Q1 2018: $1.22 million | Q2 2018: $904.7 thousand | Q3 2018: $1.01 million | Q1 2019: $292.7 thousand | Q2 2019: $102.9 thousand | Q3 2019: -$101.3 thousand | Q1 2020: -$261.5 thousand | Q2 2020: $2.30 million | Q3 2020: $2.07 million | Q1 2021: $4.23 million | Q2 2021: $3.77 million | Q3 2021: $10.15 million | Q1 2022: $8.50 million | Q2 2022: $7.87 million | Q3 2022: $11.85 million | Q1 2023: $9.44 million | Q2 2023: $8.30 million | Q3 2023: $7.50 million | Q1 2024: $5.29 million | Q2 2024: $5.96 million | Q3 2024: $6.78 million | Q1 2025: $4.01 million | Q2 2025: $4.92 million | Q3 2025: $5.01 million.
- Over the full 14 years of available data (2010 to 2025), Silo Pharma, Inc.'s Stockholders Equity has grown by 13,180.2%.
- Historical annual values: Fiscal year 2025: $6.31 million | Fiscal year 2024: $5.03 million | Fiscal year 2023: $6.18 million | Fiscal year 2022: $10.34 million | Fiscal year 2021: $9.06 million | Fiscal year 2020: $1.28 million | Fiscal year 2019: -$22.9 thousand | Fiscal year 2018: $407.4 thousand | Fiscal year 2017: $1.20 million | Fiscal year 2016: $846.5 thousand | Fiscal year 2013: $1.79 million | Fiscal year 2012: -$41.2 thousand | Fiscal year 2011: -$1.7 thousand | Fiscal year 2010: $47.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: